<DOC>
	<DOCNO>NCT02305238</DOCNO>
	<brief_summary>To assess efficacy intravitreal ( IVT ) administration aflibercept two different approach Treat Extend dose regimen Japanese subject neovascular ( wet ) Age-related Macular Degeneration ( wAMD ) . To assess safety IVT administration aflibercept two different approach Treat Extend dose regimen Japanese subject wAMD 2 year .</brief_summary>
	<brief_title>Japanese Treat Extend Study Aflibercept Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Japanese men woman ≥ 50 year age Active primary subfoveal choroidal neovascularization ( CNV ) lesion secondary wAMD , include juxtafoveal lesion affect fovea evidence fluorescein angiography ( FA ) study eye Early Treatment Diabetic Retinopathy Study ( ETDRS ) bestcorrected visual acuity ( BCVA ) 73 25 letter ( approximately 20/40 20/320 Snellen equivalent ) study eye Prior treatment study eye intraocular antiVEGF ( Vascular Endothelial Growth Factor ) agent , verteporfin photodynamic therapy ( PDT ) , laser , intraocular corticosteroid , surgical intervention ( except cataract surgery 30 day prior screen ) systemic use antiVEGF product within 3 month prior study entry Active suspect infection surround study eye Active severe intraocular inflammation study eye Intraocular pressure ( IOP ) ≥ 25 mmHg study eye Ocular condition study eye may impact vision confound study outcome</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Eylea ,</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Treat Extend regimen</keyword>
	<keyword>Age-related macular degeneration</keyword>
</DOC>